Skip to main content
. 2023 Dec 19;11(1):ofad641. doi: 10.1093/ofid/ofad641

Figure 1.

Figure 1.

Autoantibodies against IFN-β. A, The prevalence of autoantibodies against IFN-β was measured in the plasma of patients: control (n = 38), PCS (n = 128), and severe COVID-19 (n = 21). B, The neutralization effect of autoantibodies against IFN-β in plasma from 3 patients with PCS (Nos. 1–3) vs negative control. IFN, interferon; PCS, post–COVID-19 syndrome.